Brought to you by 
Eisai to use Forma’s DOS technology for drug discovery
26 Jul 2011
Executive Summary
Forma Therapeutics Inc. (small-molecule drug discovery in cancer) has granted Eisai Co. Ltd.’s US operation Eisai Inc. a nonexclusive license to use its Diversity Oriented Synthesis (DOS) chemical compound library and high-throughput cell screening platform for discovery and identification of potential drug candidates against intractable targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com